Soluble Systems

Canaccord Genuity acts as Placement Agent for $25.0 million private placement by Soluble Systems, LLC

Canaccord Genuity is pleased to announce that on October 25, 2017, it completed a private placement for Soluble Systems, LLC, whereby the Company issued $25.0 million of Series E Preferred Shares to new investors. Key participating investors included 1315 Capital and SV Health Investors LLP. Canaccord Genuity acted as Placement Agent for the financing.

Soluble Systems, LLC, a privately-held company, markets and distributes an advanced wound care product designed to help healthcare professionals treat difficult-to-heal chronic wounds. The Company’s leading product, TheraSkin, is a cryopreserved human skin allograft indicated for use in the treatment of external acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers and burns. The Company was founded in 1999 and is headquartered in Newport News, Virginia.

1315 Capital is a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology and health service companies.

SV Health Investors LLP is a leading healthcare and life sciences venture capital and growth equity firm, with over $2 billion in capital under management across seven private healthcare funds and a 20-year track record.